The path from idea to market can have twists and turns, requiring a partner who can anticipate and avoid obstacles to keep moving ahead at full speed. From research and development in the lab to the start of clinical trials, we ensure a smooth transition.
The path from idea to market can have twists and turns, requiring a partner who can anticipate and avoid obstacles to keep moving ahead at full speed. From research and development in the lab to the start of clinical trials, we ensure a smooth transition. Whether you are running clinical trials directly or through a Clinical Research Organization (CRO), it takes the right people, processes and technologies to keep things moving forward through every phase.
From project setup to the New Drug Application, we maintain safety and quality throughout the clinical trial process to ensure smooth regulatory approval. Our insight covers the following therapeutic areas:
We custom fit our services to go beyond just clinical trials — we evolve with the needs of our pharmaceutical customers. From regulatory approval, we keep the momentum building uninterrupted through to manufacturing, engineering production lines, monitoring clean room environments and testing to avoid quality-related delays. Post-market, we continue supporting our customers in Phase IV and Real World Evidence trials, evaluating efficacy, safety and side effects, and utilizing our global expertise to expand into new markets.
We can be a part of your team, integrated seamlessly, while constantly looking for ways to work more efficiently and improve processes. From providing managed resources to fill talent gaps to providing insourcing services for a project at your lab, you can be assured the process never misses a step. With competing business pressures to keep headcount down but speed up timelines, EASi helps you make your way better and faster. By focusing on communication, training and performance monitoring, we have developed leading levels of retention, ensuring confidentiality and stability while getting new drugs to the people who need them faster than ever.